Tempus AI’s shares dropped 4.1% following the earnings report, driven by cautious outlook signals despite solid revenue growth. Investor concerns likely centered on deceleration in hereditary diagnostics and tempered margin expectations implicit in the adjusted EBITDA guidance.

• Revenue of $348.1 million grew 36% year-over-year, supported by Oncology unit growth of ~28% and strong performance in solid tumor, liquid biopsies, and MRD volumes.
• Hereditary diagnostics growth slowed significantly, attributed to difficult prior-year comparables, with expectations of mid-teen growth returning only in the second half of the year.
• Data and applications revenue reached $87 million, up 40.5%, led by data licensing and modeling insights growing over 44%, with third consecutive quarter of bookings above $100 million.
• Guidance was raised to $1.59-1.6 billion in revenue for the full year with adjusted EBITDA around $65 million, implying margin pressure and more cautious profitability targets.
• Commentary highlighted solid large pharma collaborations, including new strategic deals with Merck and Gilead, yet did not fully offset investor wariness of growth pacing and margin trajectory.